Literature DB >> 7036921

Long-term azathioprine in rheumatoid arthritis: a double-blind study.

M De Silva, B L Hazleman.   

Abstract

Several studies have demonstrated the beneficial effect of azathioprine in rheumatoid arthritis. But fears have been expressed about the possible mutagenic and teratogenic effects of prolonged use. If the drug could be withdrawn once remission is achieved, and this remission be then maintained with other agents, the possible complications of long-term therapy might be avoided. A double-blind controlled study was carried out over 8 months in 32 patients receiving long-term azathioprine therapy for rheumatoid arthritis. Substitution of placebo for active drug resulted in clinical deterioration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7036921      PMCID: PMC1000830          DOI: 10.1136/ard.40.6.560

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  7 in total

1.  Immunosuppressive therapy in rheumatic diseases. A retrospective study.

Authors:  M H Thomas; W Bergen; V K Philips; N O Rothermich
Journal:  Ohio State Med J       Date:  1975-09

2.  Azathioprine in rheumatoid arthritis. A double-blind, cross over study.

Authors:  M B Urowitz; D A Gordon; H A Smythe; W Pruzanski; M A Ogryzio
Journal:  Arthritis Rheum       Date:  1973 May-Jun

3.  Azathioprine in rheumatoid arthritis: a long-term follow-up study.

Authors:  T Hunter; M B Urowitz; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Arthritis Rheum       Date:  1975 Jan-Feb

4.  Azathioprine in rheumatoid arthritis.

Authors:  M Mason; H L Currey; C G Barnes; J F Dunne; B L Hazleman; I D Strickland
Journal:  Br Med J       Date:  1969-02-15

5.  Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine.

Authors:  P Lewis; B L Hazleman; R Hanka; S Roberts
Journal:  Ann Rheum Dis       Date:  1980-10       Impact factor: 19.103

6.  Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.

Authors:  H L Currey; J Harris; R M Mason; J Woodland; T Beveridge; C J Roberts; D W Vere; A S Dixon; J Davies; B Owen-Smith
Journal:  Br Med J       Date:  1974-09-28

7.  Further experience with azathioprine in rheumatoid arthritis.

Authors:  J Harris; J D Jessop; D M Chaput de Saintonge
Journal:  Br Med J       Date:  1971-11-20
  7 in total
  13 in total

Review 1.  Treatment of vasculitis.

Authors:  H G Taylor; A Samanta
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

2.  Clinical trials: proposal for an international coding system (ICS).

Authors:  N Bellamy
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

3.  Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation.

Authors:  S ten Wolde; J Hermans; F C Breedveld; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  1997-04       Impact factor: 19.103

Review 4.  Immunosuppressive drugs and corticosteroids in the treatment of rheumatoid arthritis.

Authors:  M Arnold; L Schrieber; P Brooks
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 5.  Rational use of disease-modifying antirheumatic drugs.

Authors:  D E Furst
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

6.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 7.  New perspectives of secondary and tertiary therapy for rheumatoid arthritis.

Authors:  R F Willkens
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

8.  Immunological studies in patients with rheumatoid arthritis receiving azathioprine and myocrisin in combination.

Authors:  P Lewis; B L Hazleman; J R Park; D Y Bulgen; D Franks; C Hurd; D L Brown
Journal:  Clin Rheumatol       Date:  1982-09       Impact factor: 2.980

9.  Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.

Authors:  M De Silva; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

10.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

Authors:  Imke Tiede; Gerhard Fritz; Susanne Strand; Daniela Poppe; Radovan Dvorsky; Dennis Strand; Hans Anton Lehr; Stefan Wirtz; Christoph Becker; Raja Atreya; Jonas Mudter; Kai Hildner; Brigitte Bartsch; Martin Holtmann; Richard Blumberg; Henning Walczak; Heiko Iven; Peter R Galle; Mohammad Reza Ahmadian; Markus F Neurath
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.